Miravant Medical Technologies (OTCBB:MRVT), a pharmaceutical development company specializing in PhotoPoint(R) photodynamic therapy (PDT), today announced that proprietary drug SnET2 provided a visual acuity benefit in macular degeneration patients with occult lesions, as observed in phase III clinical trials of patients with wet age-related macular degeneration (AMD). The clinical results were presented by Edgar L. Thomas, M.D., Los Angeles, at the American Society of Retinal Specialists (ASRS) meeting, San Diego. The U.S. Food and Drug Administration (FDA) is currently reviewing Miravant’s New Drug Application (NDA) for SnET2, under a Priority Review designation.
